Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 1

Status

Completed 6

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 6

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 6Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Patients With Any Advanced Solid Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Genital Neoplasms, Female 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × nintedanib × Clear all
NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
30 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT00998296 2015-08-19

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Boehringer Ingelheim

Phase 1 Completed
70 enrolled 25 charts
Tumor-Agnostic

Neoplasms

NCT00715403 2014-12-02

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Boehringer Ingelheim

Phase 1 Completed
41 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT02182128 2014-07-18

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT02182206 2014-07-18

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡